Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma

Purpose: Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clinical development, is pr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Ocul Pharmacol Ther
Autors principals: Lin, Cheng-Wen, Sherman, Bryan, Moore, Lori A., Laethem, Carmen L., Lu, Da-Wen, Pattabiraman, Padmanabhan P., Rao, Ponugoti Vasantha, deLong, Mitchell A., Kopczynski, Casey C.
Format: Artigo
Idioma:Inglês
Publicat: Mary Ann Liebert, Inc. 2018
Matèries:
Volume 1: Glaucoma IOP, Neuroprotection and Devices
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5963640/
https://ncbi.nlm.nih.gov/pubmed/28609185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/jop.2017.0023
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars